Related Experiment Videos
Developing an approach to evaluate the use of neoplastic cells as vaccine substrates
1Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
Abstract:
Advances in technology, emerging infectious diseases and accumulating knowledge of the mechanisms of neoplastic development are stimulating the need to develop a regulatory management plan that can be used to evaluate different types of neoplastic cells as possible substrates for vaccine development. To address this challenge, CBER is developing an approach, based on issue identification, issue-based model development and validation, and, where possible, a quantitative risk evaluation, as a basis for regulatory guidance on the use of neoplastic cell substrates for the manufacture of viral vaccines. The issues or concerns that have been identified with the use of neoplastic cell substrates include vaccine contamination with viable human tumour cells or adventitious agents, the possible risks associated with residual cell-substrate DNA or proteins in the vaccine, possible vaccine virus interactions with the cell substrate, and possible uncertainties associated with the instability of the neoplastic cell genome.
Insights
Regulatory guidance is needed for using neoplastic cells in viral vaccine manufacturing. CBER is developing a risk-based approach to address safety concerns like contamination and genomic instability in tumor cell substrates.
Area of Science:
- Biotechnology
- Vaccinology
- Regulatory Science
Background:
- Technological advancements and new infectious diseases necessitate novel vaccine production methods.
- Understanding neoplastic development mechanisms informs potential cell substrates for vaccines.
- Existing methods for evaluating tumor cell substrates for vaccine manufacturing require updated regulatory frameworks.
Purpose of the Study:
- To develop a regulatory management plan for evaluating neoplastic cells as substrates for viral vaccine production.
- To establish a framework for regulatory guidance addressing safety and efficacy concerns.
- To provide a basis for assessing the suitability of tumor cell lines in vaccine manufacturing.
Main Methods:
- Issue identification and analysis regarding the use of neoplastic cell substrates.
- Development and validation of issue-based models for risk assessment.
- Quantitative risk evaluation where feasible to inform regulatory decisions.
Main Results:
- Identified key concerns including contamination with tumor cells or adventitious agents.
- Assessed risks associated with residual DNA and proteins from cell substrates.
- Evaluated potential vaccine-virus interactions and genomic instability of neoplastic cells.
Conclusions:
- A structured, risk-based approach is essential for regulating neoplastic cell substrates in vaccine manufacturing.
- Addressing contamination, residual components, and cell stability is critical for vaccine safety.
- The developed framework will guide regulatory decision-making for novel vaccine production strategies.